Ivan Borrello's guest appearances

Ivan Borrello

CureTalks

HealthTree Podcast for Multiple Myeloma

Johns Hopkins

Stephen Russell

Adam Cohen

David Siegel

Mike Thompson

Beth Israel

Damian Green

Sarah Cannon

Keith Stewart

Mark Newman

Paul Richardson

Stephen Harding

Kenneth Anderson

Vincent Rajkumar

Thomas Martin

OwlTail

One of the two projects funded by the Myeloma Crowd Research Initiative is an immunotherapy called MILs (marrow infiltrating lymphocytes). For high risk myeloma patients, their T-cells are taken out, grown up a hundred fold in the presence of their tumor and then given back a post-transplant. Dr. Borrello gives us an update on his open clinical trlal for high risk patients and shares how is also using the MILs with allogeneic transplant and other future combinations (like with checkpoint inhibitors) and in earlier settings. This immunotherapy can be used in almost 100% of patients with fewer side effects than other types of immunotherapy approaches like CAR T cells. You can support this project by donating here: The Myeloma Crowd Research Initiative (MCRI)Special thanks to our Myeloma Crowd Radio episode sponsor, Takeda Oncology.

One of the two projects funded by the Myeloma Crowd Research Initiative is an immunotherapy called MILs (marrow infiltrating lymphocytes). For high risk myeloma patients, their T-cells are taken out, grown up a hundred fold in the presence of their tumor and then given back a post-transplant. Dr. Borrello gives us an update on his open clinical trlal for high risk patients and shares how is also using the MILs with allogeneic transplant and other future combinations (like with checkpoint inhibitors) and in earlier settings. This immunotherapy can be used in almost 100% of patients with fewer side effects than other types of immunotherapy approaches like CAR T cells. <br><br>You can support this project by donating here: The Myeloma Crowd Research Initiative (MCRI)<br><br>Special thanks to our Myeloma Crowd Radio episode sponsor, Takeda Oncology.

Myeloma Crowd Radio: Ivan Borrello, MD, Johns Hopkins School of Medicine

Dr. Ivan Borrello, MD of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, joins us as part of the top 10 projects selected by the Myeloma Crowd Research Initiative. He shares his pioneering work using patients' own immune cells to fight their cancer. His group leads the research for this type of immunotherapy, called adaptive T-cell therapy with MILS (marrow infiltrating lymphocytes). This vaccine is a version for multiple myeloma of those already successful to treat pancreas, prostate and breast cancers. Learn more about this important work in his upcoming study in multiple myeloma.

Myeloma Crowd Radio/MCRI: Dr. Ivan Borrello, MD, Johns Hopkins, Immunotherapy